Urine fibroblast growth factor 23 levels in hypertensive children and adolescents

Croatian Medical Journal

Volumn 56, Issue 4, 2015, Pages 344-350

  Zajac, Magdalena ^a   Rybi Szumińska, Agnieszka ^a   Wasilewska, Anna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; MAGNESIUM; PHOSPHORUS; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ELISA KIT; FEMALE; HUMAN; HYPERTENSION; MAGNESIUM URINE LEVEL; MALE; PHOSPHATE METABOLISM; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; BLOOD; BLOOD PRESSURE; PHYSIOLOGY; URINE;

ADOLESCENT; BIOMARKERS; BLOOD PRESSURE; CALCIUM; CHILD; CREATININE; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERTENSION; MALE; PHOSPHORUS;

EID: 84941198799     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2015.56.344     Document Type: Article

References (36)

1. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49:1063-9. Medline:17372031 doi: 10.1161/HYPERTENSIONAHA.107.087288
2. Zhao G, Ford ES, Li C, Kris-Etherton PM, Etherton TD, Balluz LS. Independent associations of serum concentrations of 25- hydroxyvitamin D and parathyroid hormone with blood pressure among US adults. J Hypertens. 2010;28:1821-8. Medline:20613627 doi: 10.1097/HJH.0b013e32833bc5b4
3. Bhandari SK, Pashayan S, Liu IL, Rasgon SA, Kujubu DA, Tom TY, et al. 25-hydroxyvitamin D levels and hypertension rates. J Clin Hypertens (Greenwich). 2011;13:170-7. Medline:21366848 doi: 10.1111/j.1751-7176.2010.00408.x
4. He JL, Scragg RK. Vitamin D, parathyroid hormone, and blood pressure in the National Health and Nutrition Examination Surveys. Am J Hypertens. 2011;24:911-7. Medline:21525968 doi: 10.1038/ajh.2011.73
5. Taylor EN, Curhan GC, Forman JP. Parathyroid hormone and the risk of incident hypertension. J Hypertens. 2008;26:1390-4. Medline:18551015 doi: 10.1097/HJH.0b013e3282ffb43b
6. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calciumindependent and 1,25(OH)2D3-dependent regulation of the reninangiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74:170-9. Medline:18385669 doi: 10.1038/ki.2008.101
7. Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M, et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol. 2009;20:1504-12. Medline:19406976 doi: 10.1681/ASN.2008101106
8. Alonso A, Beunza JJ, Delgado-Rodríguez M, Martínez JA, Martínez-González MA. Low-fat dairy consumption and reduced risk of hypertension: the Seguimiento Universidad de Navarra (SUN) cohort. Am J Clin Nutr. 2005;82:972-9. Medline:16280427
9. Engberink MF, Hendriksen MA, Schouten EG, van Rooij FJ, Hofman A, Witteman JC, et al. Inverse association between dairy intake and hypertension: the Rotterdam Study. Am J Clin Nutr. 2009;89:1877-83. Medline:19369377 doi: 10.3945/ajcn.2008.27064
10. Alonso A, Nettleton JA, Ix JH, de Boer IH, Folsom AR, Bidulescu A, et al. Dietary phosphorus, blood pressure, and incidenceof hypertension in the atherosclerosis risk in communities study and themulti-ethnic study of atherosclerosis. Hypertension. 2010;55:776-84. Medline:20083730 doi: 10.1161/HYPERTENSIONAHA.109.143461
11. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of theeffects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117-24. Medline:9099655 doi: 10.1056/NEJM199704173361601
12. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47:296-308. Medline:16434724 doi: 10.1161/01.HYP.0000202568.01167.B6
13. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004;314:409-14. Medline:14733920 doi: 10.1016/j.bbrc.2003.12.102
14. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005;289:F1088-95. Medline:15998839 doi: 10.1152/ajprenal.00474.2004
15. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005;67:1171-8. Medline:15698459 doi: 10.1111/j.1523-1755.2005.00184.x
16. Ix JH, Shlipak MG, Wassel CL, Whooley MA. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant. 2010;25:993-7. Medline:20037168 doi: 10.1093/ndt/gfp699
17. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205-15. Medline:15917335 doi: 10.1681/ASN.2005010052
18. Isakova T, Gutiérrez OM, Smith K, Epstein M, Keating LK, Jüppner H, et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2011;26:584-91. Medline:20631407 doi: 10.1093/ndt/gfq419
19. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006;91:3144-9. Medline:16735491 doi: 10.1210/jc.2006-0021
20. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272-9. Medline:14633152 doi: 10.1046/j.1523-1755.2003.00328.x
21. Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med. 2014;6:744-59. Medline:24797667
22. Dai B, David V, Martin A, Huang J, Li H, Jiao Y, et al. A comparative transcriptome analysis identifying FGF23 regulated genes in thekidney of a mouse CKD model. PLoS ONE. 2012;7:e44161. Medline:22970174 doi: 10.1371/journal.pone.0044161
23. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is anegative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229-38. Medline:12122115 doi: 10.1172/JCI0215219
24. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem. 2003;88:327-31. Medline:12520534 doi: 10.1002/jcb.10343
25. Gutiérrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol. 2011;6:2871-8. Medline:22034506 doi: 10.2215/CJN.02740311
26. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al. Chronic Renal Insufficiency Cohort. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol. 2012;7:1155-62. Medline:22554719 doi: 10.2215/CJN.13281211
27. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205:385-90. Medline:19181315 doi: 10.1016/j.atherosclerosis.2009.01.001
28. London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007;18:613-20. Medline:17202417 doi: 10.1681/ASN.2006060573
29. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, et al. FGF-23 and vascular dysfunctionin patients with stage 3 and 4 chronic kidney disease. Kidney Int. 2010;78:679-85. Medline:20613714 doi: 10.1038/ki.2010.194
30. Isakova T, Xie H, Barchi-Chung A, Vargas G, Sowden N, Houston J, et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol. 2011;6:2688-95. Medline:21903990 doi: 10.2215/CJN.04290511
31. Wühl E, Witte K, Soergel M, Mehls O, Schaefer F, German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens. 2002;20:1995-2007. Medline:12359978 doi: 10.1097/00004872-200210000-00019
32. Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med. 1992;11:1305-19. Medline:1518992 doi: 10.1002/sim.4780111005
33. Kułaga Z, Litwin M, Grajda A, Kułaga K, Gurzkowska B, Gozdz M, et al; OLAF Study Group. Oscillometric blood pressure percentiles for Polish normal-weight school-aged children and adolescents. J Hypertens. 2012;30:1942-54. Medline:22828086 doi: 10.1097/HJH.0b013e328356abad
34. Kułaga Z, Litwin M, Tkaczyk M, Palczewska I, Zajaczkowska M, Zwolinska D, et al. Polish 2010 growth references for schoolaged children and adolescents. Eur J Pediatr. 2011;170:599-609. Medline:20972688 doi: 10.1007/s00431-010-1329-x
35. Delanghe JR, Speeckaert MM. Creatinine determination according to Jaffe-what does it stand for? NDT Plus. 2011;4:83-6. Medline:25984118
36. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002;87:4957-60. Medline:12414858 doi: 10.1210/jc.2002-021105